MRVI · Maravai Lifesciences Holdings, Inc. · Executive Compensation
$7.32
+0.25 (+3.54%)
At close · Oct 23
Return incl. dividend (before tax)
Market Cap
$1.90B
Shares
259.67M
Volume · Oct 23
1.45M
Avg daily vol (3M)
3.14M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Bernd Brust | Chief Executive Officer | $10,129,708 |
| William E. Martin III | Former Chief Executive Officer | $3,845,263 |
| Raj Asarpota | Chief Financial Officer | $3,506,793 |
| Peter Leddy | Chief Administrative Officer | $1,849,804 |
| Kevin Herde | Former Chief Financial Officer | $1,730,738 |
| Kurt Oreshack | Secretary and General Counsel | $1,470,977 |
| Christine Dolan | Executive Vice President and General Manager, Cygnus | $1,454,198 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| William E. Martin III | Former Chief Executive Officer | $6,380,399 |
| William Martin | Chief Executive Officer | $6,380,399 |
| Andrew Burch | Former President, Nucleic Acid Production | $2,558,244 |
| Rebecca Buzzeo | Chief Commercial Officer | $2,459,680 |
| Peter Leddy | Chief Administrative Officer | $2,363,764 |
| Kevin Herde | Chief Financial Officer | $2,339,364 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Carl Hull | Executive Chairman and Former Interim Chief Executive Officer | $5,217,013 |
| Andrew Burch | Former President, Nucleic Acid Production | $2,992,807 |
| Peter Leddy | Chief Administrative Officer | $2,827,776 |
| Kevin Herde | Chief Financial Officer | $2,793,002 |
| William Martin | Chief Executive Officer | $2,301,864 |
| William E. Martin III | Former Chief Executive Officer | $2,301,864 |
| Christine Dolan | General Manager, Cygnus Technologies | $2,263,082 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| William Martin | Chief Executive Officer | $14,523,493 |
| Carl Hull | Executive Chairman and Former Interim Chief Executive Officer | $5,480,801 |
| Peter Leddy | Chief Administrative Officer | $3,923,498 |
| Kevin Herde | Chief Financial Officer | $1,741,482 |
| Christine Dolan | General Manager, Cygnus Technologies | $1,594,953 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Carl Hull | Executive Chairman and Former Interim Chief Executive Officer | $1,780,769 |
| Christine Dolan | General Manager, Cygnus Technologies | $844,670 |
| Kevin Herde | Chief Financial Officer | $841,598 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Carl Hull | Chief Executive Officer | $2,124,160 |
| Eric Tardif | President and Executive Vice-President, Corporate Development | $1,896,348 |
| Brian Neel | Chief Operating Officer, Nucleic Acid Production | $1,861,262 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Carl Hull | Chief Executive Officer | $2,828,417 |
| Brian Neel | Chief Operating Officer, Nucleic Acid Production | $893,509 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Murali Prahalad | Board of Directors | Resigned | 2025-10-27 |
| Jessica Hopfield | Board of Directors | Resigned | 2025-10-27 |
| Benjamin Daverman | Board of Directors | Resigned | 2025-10-27 |
| Pete Leddy | Executive Vice President and Chief Administrative Officer | Terminated | 2025-08-11 |
| Rebecca Buzzeo | Executive Vice President and Chief Commercial Officer | Terminated | 2025-08-11 |
| Rajesh "Raj" Asarpota | Executive Vice President (EVP) and Chief Financial Officer (CFO) | Appointed | 2025-06-25 |
| Rajesh Asarpota | Chief Financial Officer | Appointed | 2025-06-25 |
| Bernd Brust | member of the Board of Directors | Appointed | 2025-06-09 |
| Bernd Brust | Chief Executive Officer (CEO) and a member of the Board of Directors | Appointed | 2025-06-09 |
| William E. Martin, III | member of the Board | Resigned | 2025-06-09 |
| Bernd Brust | member of the Board | Appointed | 2025-06-09 |
| Bernd Brust | Chief Executive Officer | Appointed | 2025-06-09 |
| Andrew Burch | President, Nucleic Acid Production | Terminated | 2025-01-08 |
| R. Andrew Eckert | Chairman of the Board | Appointed | 2024-12-05 |
| Robert Andrew Eckert | director | Appointed | 2024-12-05 |
| Robert Andrew Eckert | Chairman of the Board | Appointed | 2024-12-05 |
| Carl Hull | member of the Board of Directors | Resigned | 2024-12-05 |
| Carl Hull | Executive Chairman of the Board | Retired | 2024-12-05 |
| William "Trey" Martin, III | Class III director | Appointed | 2024-07-29 |
| Anat Ashkenazi | director | Resigned | 2024-06-12 |
| William "Trey" Martin, III | Chief Executive Officer | Appointed | 2023-07-27 |
| John DeFord | director | Appointed | 2023-07-20 |
| Robert B. Hance | director | Resigned | 2023-07-20 |
| Andrew Burch | Executive Vice President and General Manager of the Company's Nucleic Acid Products Operating Division | Appointed | 2023-03-13 |
| Brian Neel | Chief Operating Officer, Nucleic Acid Production | Resigned | 2023-03-13 |
Leadership
- Bernd Brust CEO, Board Member
- William "Trey" Martin, III CEO, Board Member
- William E. Martin III CEO
- William Martin CEO
- Carl W. Hull Chairman
- R. Andrew Eckert Chairman, Board Member
- Robert Andrew Eckert Chairman, Board Member
- Kevin Herde CFO
- Raj Asarpota CFO
- Rajesh "Raj" Asarpota CFO
- Brian Neel COO
- Christine Dolan COO
- Kurt Oreshack General Counsel
- Constantine Mihas Board Member
- Gregory T. Lucier Board Member
- John DeFord Board Member
- Luke Marker Board Member
- Sean Cunningham Board Member
- Susannah Gray Board Member
Key facts
CIK
1823239
CUSIP
56600D107
13F (30d)
15 filings
15 filers
Visit website
Investor relations